14.08
-0.09 (-0.64%)
| 前收盘价格 | 14.17 |
| 收盘价格 | 14.12 |
| 成交量 | 291,453 |
| 平均成交量 (3个月) | 801,587 |
| 市值 | 4,982,433,280 |
| 预期市盈率 (P/E Forward) | 21.88 |
| 价格/销量 (P/S) | 1.02 |
| 股市价格/股市净资产 (P/B) | 0.780 |
| 52周波幅 | |
| 利润日期 | 29 Oct 2025 |
| 营业毛利率 | -7.50% |
| 营业利益率 (TTM) | -5.36% |
| 稀释每股收益 (EPS TTM) | -1.02 |
| 季度收入增长率 (YOY) | 3.50% |
| 总债务/股东权益 (D/E MRQ) | 75.07% |
| 流动比率 (MRQ) | 1.56 |
| 营业现金流 (OCF TTM) | 166.00 M |
| 杠杆自由现金流 (LFCF TTM) | 69.00 M |
| 资产报酬率 (ROA TTM) | 0.61% |
| 股东权益报酬率 (ROE TTM) | -5.36% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Medical Instruments & Supplies (US) | 混合的 | 看跌 |
| Medical Instruments & Supplies (全球的) | 看跌 | 看跌 | |
| 股票 | Bausch + Lomb Corporation | 混合的 | 看跌 |
AIStockmoo 评分
| 分析师共识 | 0.5 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 0.5 |
| 平均 | -0.25 |
|
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space. |
|
| 部门 | Healthcare |
| 行业 | Medical Instruments & Supplies |
| 投资方式 | Mid Core |
| 内部持股比例 | 88.13% |
| 机构持股比例 | 10.97% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Icahn Carl C | 31 Mar 2025 | 3,500,000 |
| Goldentree Asset Management Lp | 30 Jun 2025 | 2,583,185 |
| Oaktree Capital Management Lp | 30 Jun 2025 | 2,521,245 |
| Maple Rock Capital Partners Inc. | 31 Mar 2025 | 1,971,053 |
| Whitebox Advisors Llc | 31 Mar 2025 | 1,622,876 |
| Nomura Holdings Inc | 31 Mar 2025 | 1,256,181 |
| Clearline Capital Lp | 31 Mar 2025 | 893,790 |
| Clark Estates Inc/Ny | 30 Jun 2025 | 850,000 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 16.00 (HC Wainwright & Co., 13.64%) | 购买 |
| 16.00 (Evercore ISI Group, 13.64%) | 购买 | |
| 16.00 (Barclays, 13.64%) | 保留 | |
| 中 | 15.50 (10.09%) | |
| 低 | 13.00 (Morgan Stanley, -7.67%) | 保留 |
| 平均值 | 15.17 (7.74%) | |
| 总计 | 2 购买, 4 保留 | |
| 平均价格@调整类型 | 13.47 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Morgan Stanley | 01 Aug 2025 | 13.00 (-7.67%) | 保留 | 13.50 |
| HC Wainwright & Co. | 31 Jul 2025 | 16.00 (13.64%) | 购买 | 13.63 |
| Wells Fargo | 31 Jul 2025 | 15.00 (6.53%) | 保留 | 13.63 |
| Citigroup | 09 Jul 2025 | 15.00 (6.53%) | 保留 | 14.05 |
| Evercore ISI Group | 08 Jul 2025 | 16.00 (13.64%) | 购买 | 14.00 |
| Barclays | 09 Jun 2025 | 16.00 (13.64%) | 保留 | 11.98 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合